Information Provided By: 
Fly News Breaks for August 28, 2019
MD
Aug 28, 2019 | 05:14 EDT
Mizuho analyst Ann Hynes says that given the headwinds in its base business, she now expects a continued low level of acquisition activity for Mednax not just in 2019, but also in 2020. The analyst lowered her 2020 adjusted EBITDA estimate to $505M from $523M, below the consensus at $513M. She also dropped her price target for the shares to $23 from $24 and keeps a Neutral rating on Mednax.
News For MD From the Last 2 Days
There are no results for your query MD
